Quick Answer
EXAGEN INC. reported Research And Development Expense of $6.25 million for the year ending 2025.
- EXAGEN INC. showed an increase of +16.4% in Research And Development Expense from 2024 to 2025.
- This data is from EXAGEN INC.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: $525.0 thousand | Q1 2019: $513.0 thousand | Q2 2019: $590.0 thousand | Q3 2019: $507.0 thousand | Q1 2020: $634.0 thousand | Q2 2020: $751.0 thousand | Q3 2020: $1.02 million | Q1 2021: $1.40 million | Q2 2021: $1.89 million | Q3 2021: $1.74 million | Q1 2022: $2.10 million | Q2 2022: $2.69 million | Q3 2022: $2.38 million | Q1 2023: $1.13 million | Q2 2023: $1.26 million | Q3 2023: $1.40 million | Q1 2024: $1.06 million | Q2 2024: $1.18 million | Q3 2024: $1.48 million | Q1 2025: $1.28 million | Q2 2025: $1.48 million | Q3 2025: $1.73 million.
- Over the full 8 years of available data (2018 to 2025), EXAGEN INC.'s Research And Development Expense has grown by 194.3%.
- Historical annual values: Fiscal year 2025: $6.25 million | Fiscal year 2024: $5.38 million | Fiscal year 2023: $4.87 million | Fiscal year 2022: $9.88 million | Fiscal year 2021: $7.24 million | Fiscal year 2020: $3.57 million | Fiscal year 2019: $2.18 million | Fiscal year 2018: $2.13 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: